Physician profile
Robert I Fox
NPI 1740305432
$36,183.81
in general payments reported to CMS, 2019-2025
33 companies · $9,760 in 2025
The $9,760 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,618 · 2020: $443 · 2021: $282 · 2022: $3,149 · 2023: $5,556 · 2024: $15K · 2025: $9,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Food and Beverage: $2,011 · Travel and Lodging: $1,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,451.25 |
| Food and Beverage | $2,010.90 |
| Travel and Lodging | $1,229.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $11,514.00 | 2019-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $8,850.00 | 2024 | |
| Glaxosmithkline, LLC. | $6,750.00 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $4,935.00 | 2022-2023 | |
| Abbvie INC. | $1,204.62 | 2019-2025 | |
| Csl Behring | $600.00 | 2022 | |
| Janssen Scientific Affairs, LLC | $450.73 | 2019-2023 | Tremfya |
| Neurocrine Biosciences, INC. | $218.46 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $161.91 | 2019-2023 | Sotyktu |
| Ucb, INC. | $130.95 | 2024 | Bimzelx |
| Lilly USA, LLC | $129.65 | 2019 | |
| Pfizer INC. | $124.56 | 2019-2024 | |
| Amgen INC. | $118.15 | 2019-2020 | |
| Horizon Therapeutics Plc | $115.65 | 2019-2020 | |
| Janssen Biotech, INC. | $106.14 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $104.36 | 2023 | Trudhesa |
| Kyowa Kirin, INC. | $93.56 | 2024 | Crysvita |
| Genentech USA, INC. | $74.04 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $64.07 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $62.02 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $51.54 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $43.22 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.21 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $34.32 | 2024 | |
| Radius Health, INC. | $33.04 | 2019 | |
| Shire North American Group INC | $28.63 | 2019 | |
| Biogen, INC. | $26.06 | 2025 | Leqembi |
| Acadia Pharmaceuticals INC | $24.65 | 2025 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $22.45 | 2020 | |
| Scilex Pharmaceuticals INC. | $21.01 | 2024 | |
| Celgene Corporation | $18.19 | 2019 | |
| Upsher-Smith Laboratories LLC | $18.12 | 2023 | |
| Fidia Pharma USA INC. | $15.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.